Reports (1519)

  • Adolescent, Child, Clinical Trials as Topic legislation & jurisprudence, Clinical Trials as Topic standards, Drug Approval legislation & jurisprudence, Drug Evaluation legislation & jurisprudence, Drug Industry legislation & jurisprudence,
    Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus, Human Herpesvirus 8.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Access to Information, Clinical Trials as Topic , Information Dissemination, International Cooperation, Pharmaceutical Preparations ,
    Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Behavioral Sciences, Brain , Clinical Medicine, Research Support as Topic, Social Medicine, United States,
    Hepatitis Viruses.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Clinical Trials as Topic, standards , Decision Making, Quality Control, Research Design,
    Hormonal Contraception and Post-menopausal Hormonal Therapy.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Clinical Trials as Topic, standards, Ethics, Research, Human Experimentation, standards , Neoplasms, Patient Rights, Research Subjects, United States,
    Human Immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Clinical Laboratory Techniques economics, Medicare economics, Prospective Payment System, United States
    Human Papillomaviruses.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Clinical Protocols, Human Experimentation, Patient Rights, Safety
    Inorganic and Organic Lead Compounds.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Clinical Trials as Topic, Information Dissemination
    Ionizing Radiation, Part 1: X- and Gamma Radiation, and Neutrons.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Genetics, Medical , Health Policy, Risk Factors, United States,
    Ionizing Radiation, Part 2: Some Internally Deposited Radionuclides.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Diffusion of Innovation, Evidence-Based Medicine, Genetics, Medical, Genomics , Medical Informatics, United States,
    Man-made Vitreous Fibres.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Diagnosis, Differential, Genetic Testing , Genetics, Medical, Genomics, Precision Medicine,
    Occupational Exposures in Insecticide Application, and Some Pesticides.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Biomarkers, Genetics, Social Medicine, methods ,
    Occupational Exposures of Hairdressers and Barbers and Personal Use of Hair Colourants; Some Hair Dyes, Cosmetic Colourants, Industrial Dyestuffs and Aromatic Amines.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Bioethics, Biomarkers, Demography, Genetics, Medical, Research , Social Medicine ,
    Occupational Exposures to Mists and Vapours from Strong Inorganic Acids; and Other Industrial Chemicals.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Carcinogens, Environmental, Environmental Exposure, Neoplasms, etiology , Neoplasms, genetics,
    Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Japan, Nuclear Warfare history, Radiation Genetics, Radiation Injuries genetics
    Painting, Firefighting, and Shiftwork.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Genetics, Medical economics, Genomics economics
    Pentachlorophenol and Some Related Compounds.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Alzheimer Disease , Biomedical Research, Translational Medical Research,
    Polychlorinated Biphenyls and Polybrominated Biphenyls.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Biomedical Research, Neurodegenerative Diseases, Research Design
    Polychlorinated Dibenzo-para-dioxins and Polychlorinated Dibenzofurans.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Africa South of the Sahara, Health Services Accessibility, Medically Underserved Area, Mental Disorders drug therapy, Nervous System Diseases drug therapy, Pharmaceutical Preparations supply & distribution, Substance-Related Disorders drug therapy
    Printing Processes and Printing Inks, Carbon Black and Some Nitro Compounds.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Health Policy, Military Medicine, Prion Diseases, diagnosis, Prion Diseases, prevention & control , Public Health, United States,
    Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Communicable Diseases, epidemiology , Datasets as Topic, Global Health, Population Surveillance,
    Silica, Some Silicates, Coal Dust and para-Aramid Fibrils.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access
  • Communicable Disease Control, methods , Disease Outbreaks, prevention & control, Health Communication, methods , Mass Media, statistics & numerical data, United States,
    Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Arthritis, Rheumatoid, therapy , Chronic Disease, therapy, Delivery of Health Care, trends, Lupus Erythematosus, Systemic, therapy, Outcome Assessment, Health Care, United States,
    Solar and Ultraviolet Radiation.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Communicable Disease Control, trends , Global Health, Health Policy, Immunization, trends , Virus Diseases, prevention & control ,
    Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Aggression, Disease Outbreaks, Evidence-Based Practice, Global Health, Violence, prevention & control ,
    Some Chemicals Used as Solvents and in Polymer Manufacture.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Delivery of Health Care, standards , Disease, classification , Quality of Health Care, United States,
    Some Drinking-water Disinfectants and Contaminants, including Arsenic.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Communicable Disease Control, trends , Health Workforce, Public Health, education,
    Some Flame Retardants and Textile Chemicals, and Exposures in the Textile Manufacturing Industry.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Bioterrorism, prevention & control, Communicable Disease Control, Disaster Planning , Disasters, Health Policy, Public Health Administration, Security Measures , United States,
    Some Industrial Chemicals.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Disease Susceptibility , Environmental Exposure, Sex Factors , Women's Health,
    Some Nanomaterials and Some Fibres.

    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans

    Get Access
  • Communicable Disease Control, Global Burden of Disease, Global Health , International Cooperation, Internationality, United States,
    Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures.

    IARC Working Group on the Evaluation of Carcinogenic Risk to Humans

    Get Access

Your Feedback